Abstract
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.
Similar content being viewed by others
References
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
American Thoracic Society. Classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;65:277–304.
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med. 2000;161:646–664.
Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66:462–467.
Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. 2001;164:1722–1727.
Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003;168:531–537.
Hansell DM, Bankier AA, Macmahon H, McLoud TC, Muller NL, Remy J. Fleischner Society glossary of terms for thoracic imaging. Radiology. 2008;246:697–722.
Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–643.
King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon gamma-1b for idiopathic pulmonary fibrosis. Chest. 2005;127:171–177
Raghu G, Brown KK, Bradford WZ, et al. A placebocontrolled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125–133.
Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229–2242.
King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75–81.
Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo controlled trial. Am J Respir Crit Care Med. 2008;178:948–955.
King, T. E. Jr, Albera C, Bradford WZ, et al.; INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo controlled trial. Lancet. 2009;374:222–228.
Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet. 2011;377:1727–1729.
Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–829
The Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363: 620–628.
Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis. Randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181:604–610.
Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:1084–1090.
Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157:1301–1315.
Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol. 2008;153:S367–S378.
Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc. 2006;3:364–372.
Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2003;(3):CD002880.
Bradley B, Branley HM, Egan JJ, et al.; British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee Thoracic Society of Australia New Zealand Thoracic Society Irish Thoracic Society. Interstitial lung disease guidelines. The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(suppl. 5):v1–v58
Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am rev Respir Dis. 1991;144:291–296.
Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2003;(3):CD003134.
Collard HR, Ryu JH, Douglas WW, et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest. 2004;125:2169–2174.
Payne K, Newman W, Fargher E et al. TPMT testing in rheumatology: any better than routine monitoring? Rheumatology. 2007;46:727–729.
Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2285–2287.
Nicod LP. Pirfenidone in IPF. Lancet. 1999;354:268–269.
Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–1047.
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet. 2011;377:1760–1769.
Spagnolo P, Del Giovane C, Luppi F, et al. Nonsteroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2010(8;9):CD003134.
Ziesche R., Hofbauer E., Wittmann K., Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999;341:1264–1269.
Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114:1308–1316
Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129:746–752.
Corte, TJ, Wort SJ, Wells AU. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:7–19.
Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360:895–900.
Mubarak K. Sildenafil in idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:2170
Maher TM. Sildenafil in idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:2169
Imokawa S, Sato A, Hayakawa H, Kotani M, Urano T, Takada A. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med. 1997;156:631–636.
Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005;128:1475–1482.
Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27:136–142.
Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis. Chest. 2006;129:794–800.
Han MK. High prevalence of abnormal acid gastrooesophageal reflux in idiopathic pulmonary fibrosis. Eur Resp J. 2006;28:884–885.
Hubbard RB, Smith C, Jeune I. The association between idiopathic pulmonary fibrosis and vascular disease. Am J Respir Crit Care Med. 2008;178:1257–1261.
Alfredo NC, Santana RA, Kairalla CR, et al. Potential role of statin use in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:1048.
Watts KL, Sampson EM, Schultz GS, Spiteri MA. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol. 2005;32:290–300.
Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest. 2004;126:438–446.
Naji NA, Connor MC, Donnelly SC, McDonnell TJ. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehab. 2006;26:237–243.
Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008;13:394–399.
Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63:549–554.
Mogulkoc N, Brutsche MH, Bishop PW, Greaves SM, Horrocks AW, Egan JJ. Pulmonary function in Idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med. 2001;164:103–108.
Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update. J Heart Lung Transplant. 2006;25:745–55.
Whelan P, Dunitz JM, Kelly RF, et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant. 2005;24:1269–1274.
Souza CA, Müller NL, Flint J, et al. Idiopathic pulmonary fibrosis: spectrum of high-resolution CT findings. AJR Am J Roentgenol. 2005;185:1531–1539.
Ma Y, Seneviratne CK, Koss M. Idiopathic pulmonary fibrosis and malignancy. Curr Opin Pulm Med. 2001;7:278–282.
Jeon TY, Lee KS, Yi CA, et al. Incremental value of PET/CT over CT for mediastinal nodal staging of non-small cell lung cancer: comparison between patients with and without idiopathic pulmonary fibrosis. AJR Am J Roentgenol. 2010;195:370–376.
Geraghty PR, Kee ST, McFarlane G, et al. CT-guided transthoracic needle aspiration biopsy of pulmonary nodules: needle size and pneumothorax rate. Radiology. 2003;229:475–481.
Richardson CM, Pointon KS, Manhire AR, Macfarlane JT. Percutaneous lung biopsies: a survey of UK practice based on 5444 biopsies. Br J Radiol. 2002;75:731–735.
Nyman J, Johansson K-A, Hultén U. Stereotactic hypofractionated radiotherapy for stage I nonsmall cell lung cancer — mature results for medically inoperable patients. Lung Cancer. 2006;51:97–103.
The University of Texas MD Anderson Cancer Center. International randomized study to compare CyberKnife® stereotactic radiosurgery with surgical resection in stage I non-small cell lung cancer. Study Summary. http://utm-ext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/Index/2007-0870. Accessed July 1, 2011.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
O’Connell, O.J., Kennedy, M.P. & Henry, M.T. Idiopathic pulmonary fibrosis: Treatment update. Adv Therapy 28, 986–999 (2011). https://doi.org/10.1007/s12325-011-0066-5
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-011-0066-5